Overweight and obesity association with mortality in patients with heart failure and reduced or preserved ejection fraction-a cohort study
PLOS One · 2026
DOI: 10.1371/journal.pone.0341606 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Nicolas Garin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Riviera Chablais Hospital, Rennaz, Switzerland. Hauptthemen laut MEDLINE: Heart Failure, Obesity, Stroke Volume, Overweight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Obesity is a risk factor for incident heart failure, but patients with excess weight and heart failure have lower mortality. This “obesity paradox” may be explained either by a favourable effect of the adipose tissue or by confounding. We aimed to assess if body mass index (BMI) is associated with lower mortality after extensive adjustment for prognostic factors in patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction.
Methods
Prospective, observational study including consecutive patients hospitalized for acute heart failure. Two years hazard of mortality was assessed in a multivariable Cox model, in the whole population and separately for HFrEF and HFpEF.
Results
Among 957 included patients (mean age 76 years, 41% women), 500 (47%) had HFrEF and 443 (53%) HFpEF. Four hundred (39%) were in the normoweight, 301(30%) in the overweight, and 256(25%) in the obese category (Class I obesity:144 patients; class II or III: 112). Corresponding mortality was 37%, 26% and 22%. Unadjusted hazard ratio (HR) for mortality was 0.96 (95% CI 0.94–0.98) for each BMI point in the whole population, 0.97 (95% CI 0.94–1.02) in patients with HFrEF, and 0.94 (95% CI 0.92–0.97) in HFpEF. After adjustment for age, sex, atrial fibrillation, diabetes, chronic obstructive pulmonary disease, chronic anaemia, hypertension, glomerular filtration rate, and NT-proBNP, HR was 1.00 (95% CI 0.96–1.02) in the whole population, 1.02 (0.96–1.07) in HFrEF, and 0.98 (95% CI 0.94–1.01) in HFpEF.
Conclusions
Excess weight was associated with an apparent survival benefit in patients with acute heart failure, particularly in patients with HFpEF. This advantage disappeared completely after adjustment for confounding factors including NT-proBNP. The obesity paradox can be completely explained by differences in demographics, co-morbidities, and severity of heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Internal Medicine, Riviera Chablais Hospital, Rennaz, Switzerland.
- Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
- Faculty of Medicine, Geneva University, Geneva, Switzerland.
- Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
- Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.
ORCID-Profile: Nicolas Garin, David Carballo
Zitieren
APA
Garin, N., Carballo, D., Dash, J., Stirnemann, J., Reny, J. L., Vuilleumier, N., & Carballo, S. (2026). Overweight and obesity association with mortality in patients with heart failure and reduced or preserved ejection fraction-a cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0341606
Vancouver
Garin N, Carballo D, Dash J, Stirnemann J, Reny JL, Vuilleumier N, et al. Overweight and obesity association with mortality in patients with heart failure and reduced or preserved ejection fraction-a cohort study. PLOS One. 2026. doi:10.1371/journal.pone.0341606
BibTeX
@article{Garin2026,
author = {Garin, Nicolas and Carballo, David and Dash, Jonathan and Stirnemann, Jérôme and Reny, Jean-Luc and Vuilleumier, Nicolas and Carballo, Sebastian},
title = {Overweight and obesity association with mortality in patients with heart failure and reduced or preserved ejection fraction-a cohort study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0341606}
}
EUVIMED